1. Home
  2. Companies
  3. PKY
  4. Material Events

Pathkey.AI (ASX:PKY) — Material Events

ASX:PKY · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 4 articles Routine 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Pathkey.AI Completes Chipforge Acquisition to Expand AI Chip Design ReachMedium
Pathkey.AI completes acquisition of AI semiconductor design firm Chipforge
23 June 2026 ·Acquisition Completion ·85
Pathkey.AI Elevates TrialKey with Drug-Level AI, Pioneering Drug DiscoveryMedium
Pathkey.AI upgrades TrialKey with drug-level AI features, advancing into AI-driven drug discovery
18 Sept 2025 ·ASX Announcement ·85
Pathkey.AI’s TrialKey AI Predicts Clinical Trial Success with 73% AccuracyMedium
Pathkey.AI's TrialKey AI Platform Predicts Clinical Trial Success with 73% Accuracy and +76% Average Share Price Gains
8 Sept 2025 ·ASX Announcement ·85
Pathkey.AI Secures $2.8M Placement with Sam Weiss as Strategic AdvisorMedium
Pathkey.AI appoints Sam Weiss as strategic advisor and raises $2.8 million placement
12 Aug 2026 ·Capital Raising and Strategic Appointment ·85
Pathkey.AI Raises A$3.48m to Accelerate AI Growth with New Board LeadershipMedium
Pathkey.AI raises A$3.48m via placement and rights issue, appoints new chair to accelerate AI growth
27 Nov 2025 ·Capital Raising ·80
Pathkey.AI Strengthens Board, Raises $3.5m to Expand AI Beyond HealthcareMedium
Pathkey.AI advances TrialKey platform, strengthens board, raises $3.5m to fuel AI growth beyond healthcare
30 Jan 2026 ·Quarterly Report and Appendix 4C ·75
Pathkey Names Defence Tech Veteran Andrew Farnsworth as CEO to Accelerate AI GrowthMedium
Pathkey Appoints Andrew Farnsworth as CEO to Drive AI Platform Growth and Commercialisation
11 May 2026 ·Executive Appointment ·75
Pathkey.AI’s TrialKey AI Drives 43.6% Average Share Price Jump on Clinical Trial WinsMedium
Pathkey.AI's TrialKey AI Shows 43.6% Average Share Price Gain on Clinical Trial Predictions
9 Oct 2025 ·ASX Announcement ·75
Pathkey.AI Validates AI Platform and Revamps Board Amid Commercial PushMedium
Pathkey.AI validates AI platform, renews board, maintains financial discipline, and advances commercial growth
31 Oct 2025 ·Quarterly Activities and Cash Flow Report ·75
How Pathkey.AI’s New Partnership Could Revolutionise Early-Phase Clinical TrialsMedium
Pathkey.AI and Armstrong Clinical Partner to Enhance Early-Phase Clinical Trial Success Using AI
12 Nov 2025 ·Collaboration Agreement Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.